James M. Hindman

James M. Hindman has served as a member of the board of directors since May 2020. Mr. Hindman has over 30 years of global and strategic financial experience in the biopharmaceutical and medical device industries, including the urology, ophthalmology, neurology, dermatology, and medical aesthetics therapeutic areas. He enjoyed a long and successful career at Allergan, most recently serving as Chief Financial Officer and Executive Vice President of Finance and Business Development until Allergan’s $70.5B sale to Actavis in 2015. Under Mr. Hindman’s leadership, Allergan achieved its most robust financial performance in the company’s then 60+-year history. He was instrumental in facilitating the largest restructuring of Allergan, creating $20B in shareholder value that ultimately led to the Actavis acquisition and the creation of a top 10 global pharmaceutical firm. In addition to serving as Chief Financial Officer, Mr. Hindman held various senior leadership positions during his tenure at Allergan, including Senior Vice President, Finance, and Controller. He also led several strategic functions at the company, including treasury, investor relations, risk, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009 to 2015. Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves on the boards of Millendo Therapeutics, Accuray, Inc, and Aatru Medical, and is a member of the Loyola Marymount University Board of Regents.